Microbot Medical (NASDAQ:MBOT) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Microbot Medical (NASDAQ:MBOT - Free Report) from a sell rating to a hold rating in a research note released on Saturday morning.

Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Microbot Medical in a research report on Thursday, April 10th.

Microbot Medical Stock Performance

Shares of MBOT stock traded down $0.03 during trading hours on Friday, reaching $2.42. The company had a trading volume of 714,801 shares, compared to its average volume of 1,738,598. The business has a fifty day moving average price of $2.49 and a 200-day moving average price of $1.89. Microbot Medical has a one year low of $0.82 and a one year high of $3.38. The firm has a market cap of $88.04 million, a PE ratio of -3.72 and a beta of 1.14.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.07. Equities research analysts forecast that Microbot Medical will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Microbot Medical

A number of hedge funds have recently modified their holdings of MBOT. Geode Capital Management LLC lifted its holdings in shares of Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after buying an additional 10,442 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Microbot Medical in the first quarter worth $42,000. Goldman Sachs Group Inc. purchased a new position in shares of Microbot Medical in the first quarter worth $57,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Microbot Medical in the fourth quarter worth $118,000. 16.30% of the stock is currently owned by institutional investors.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.